Replimune to Present at the 41st Annual J.P. Morgan Healthcare Conference
WOBURN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) — Replimune Group, Inc. (Nasdaq: REPL), a clinical…
WOBURN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) — Replimune Group, Inc. (Nasdaq: REPL), a clinical…
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT),…
Cell Therapy Veteran and Former Kite Pharma Clinical Leader to Head Development of Expanding Portfolio…
FDA Fast-Track designation was granted to investigate abelacimab for the prevention of stroke and systemic…
All three sickle cell disease participants treated with briquilimab successfully engrafted with neutrophil engraftment within…
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX),…
MHRA denies Oral Paclitaxel for metastatic breast cancer based solely on chemistry, manufacturing and control…
COPENHAGEN, Denmark, Jan. 03, 2023 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) announced today…
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company…
ODENSE, Denmark, Jan. 03, 2023 (GLOBE NEWSWIRE) — Alphalyse has performed the world’s first GMP-certified…
COPENHAGEN, Denmark, Jan. 03, 2023 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or…
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage…
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a life sciences company…
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage…
NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) — Dante Genomics, a global leader in genomics…
New Seven-Figure Contract Expected to Move Company Into The Black SAN JOSE, Calif., Jan. 03,…
Highlights Infinity Stone to participate as an exhibitor at the Future Minerals Forum in Riyadh,…
Toronto, Ontario–(Newsfile Corp. – January 3, 2023) – DGTL Holdings Inc. (TSXV: DGTL) (“DGTL” or…
Sanguina leveraged recent study results to inform its new Premium Subscription featuring “MyMobile,” a personalized…
New 13th Gen Intel Core mobile processors drive unrivaled performance and superior experiences for over…